Breast Cancer Spread to the Brain: What You Need to Know

Written by: Dana-Farber Editorial Team
Medically Reviewed By: Nancy Lin, MD

When breast cancer spreads, or metastasizes, it’s more likely to travel to some parts of the body than others. The most common sites of metastasis include the bones, brain, liver, or lungs. 

It’s rare for patients with early-stage breast cancer, which has not spread beyond the breast or adjacent lymph nodes, to develop a brain metastasis: The brain is the first site where breast cancer spreads in fewer than 5% of these patients.   

Among patients diagnosed with breast cancer that has already spread, however, between 10% and 50% develop a brain metastasis, depending on the subtype of breast cancer and other factors. 

The Program for Patients with Breast Cancer Brain Metastases in the Susan F. Smith Center for Women’s Cancers at Dana-Farber provides care from a team of experts including medical oncologists, radiation oncologists, neurosurgeons, neuro-oncologists, neuroradiologists, and pathologists. Patients receive a personalized treatment plan based on their unique situation and the specific nature of their disease. 

Dana-Farber’s Breast Cancer Brain Metastases leadership team.

What are possible symptoms of breast cancer metastasis to the brain? 

Possible symptoms of breast cancer metastasis to the brain can include: 

  • Headache 
  • Nausea or vomiting 
  • Dizziness 
  • Weakness or paralysis on one side of the body 
  • Balance problems 
  • Changes in vision 
  • Changes in mood or behavior 
  • Seizures 
  • Problems with speech 

These symptoms can be caused by factors other than breast cancer. If you’re experiencing any of them, it’s important to be examined by a doctor. 

How is brain metastasis diagnosed? 

To determine if metastasis to the brain has occurred, your doctor will likely order a magnetic resonance imaging (MRI) scan. If an MRI isn’t feasible, a computed tomography (CT) scan may be used instead. 

What are the major risk factors for brain metastasis? 

Scientists do not yet know why breast cancer is more likely to spread to some parts of the body than others, but some factors that increase the risk of spread to the brain have been identified: 

  • Being diagnosed with breast cancer while relatively young, particularly before age 35. 
  • Having a breast cancer that has already spread to the lungs. 
  • Certain subtypes of breast cancer, such as HER2-positive or triple-negative. 

How is metastatic breast cancer treated? 

Although metastatic breast cancer currently can’t be cured, it can be treatable with hormonal therapy, chemotherapy, biologic targeted treatments, and novel drug combinations. 

Treatment for brain metastases — whether originating in the breast or other part of the body — takes a variety of forms, including: 

  • Surgery 
  • Radiation therapy 
  • Systemic treatment such as chemotherapy and/or targeted therapy 

Care teams at the Metastatic Breast Cancer Program at Dana-Farber develop personalized treatment approaches for each patient’s specific type of cancer, as well as an individual plan of care and support for them and their loved ones. 

What is the prognosis for patients? 

The prognosis depends on a variety of factors, including the subtype of breast cancer a patient has. Advances in treatment approaches have led to lengthened survival for many patients, particularly those with HER2-positive breast cancer. 

What is some of the latest research in this area? 

Dana-Farber/Brigham Cancer Center offers an array of trials for patients with brain metastases, as well as patients who have leptomeningeal disease (LMD, cancer that has spread to the lining of the brain and/or spinal fluid).  

Dana-Farber investigators including Nancy Lin, MD, have led studies of the oral drug tucatinib, which targets the HER2 protein. The HER2CLIMB study included patients with HER2-positive breast cancer who had been previously treated with Herceptin®, Perjeta®, chemotherapy, and T-DM1 but whose disease had worsened. Participants, including patients with and without brain metastases, received either tucatinib or a placebo in addition to a traditional regimen of Herceptin® and the oral chemotherapy agent capecitabine. Results of the clinical trial demonstrated that in nearly 300 patients with brain metastases including in the study, the three-drug regimen more than doubled the chance of tumor shrinkage in the brain, extended the length of disease control in both the brain and body, and doubled the overall survival at two years. With these results, HER2CLIMB became the first large, randomized clinical trial to demonstrate that systemic treatment can improve outcomes in patients with HER2-positive breast cancer that has spread to the brain, and the first targeted drug approved by the FDA for the treatment of patients with brain metastases. 

Dana-Farber investigators have also led multiple other studies testing new approaches to treating patients whose breast cancer has spread to the brain. Rachel Freedman, MD, reported on a trial that tested the drugs neratinib and capecitabine in patients with HER2-positive breast cancer with brain metastases. About 50% of patients experienced a response to the therapy. In the next part of the study, Freedman found that combining ado-trastuzumab emtansine (Kadcyla) with neratinib is also an effective therapy in some patients, even those who have previously been treated with ado-trastuzumab emtansine. Ongoing trials are combining antibody drug conjugate medications such as trastuzumab deruxtecan with HER2-targeted oral drugs (such as tucatinib or ZN-A-1041) in patients with or without brain metastases. Finally, Dana-Farber has launched a clinical trial, the BRIDGET study, led by Sarah Sammons, MD, to explore whether adding tucatinib after a course of radiation might have the potential to delay or prevent progression of cancer in the brain.          

In laboratory research, Dana-Farber’s Jean Zhao, PhD, in collaboration with Nancy Lin, MD, and Jose Pablo Leone, MD, has tested new targeted regimens in order to identify the most promising regimens to take into clinical trials. Already, two of the regimens that have been tested in the laboratory have been translated into phase 2 clinical trials, and a third is anticipated to enter a clinical study by late 2023.  

About the Medical Reviewer

Nancy Lin, MD

Dr. Lin is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain.


Dr. Lin received her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women's Hospital and went on to complete fellowships in medical oncology and hematology at Dana-Farber. In 2005, she joined the staff of Brigham and Women's and Dana-Farber, where she is a medical oncologist and clinical investigator in the Breast Oncology Center.